QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering

QIAGEN N.V. (NYSE:QGEN) stands out as a potential candidate for quality investors, meeting key criteria for long-term growth, profitability, and financial health. The company, which specializes in molecular diagnostics and life sciences tools, has demonstrated strong fundamentals that align with the principles of quality investing.

Key Strengths of QIAGEN

• Revenue and EBIT Growth: Over the past five years, QGEN has delivered solid revenue growth at an annual rate of 7.8%, while EBIT growth has been even stronger at 9.6%. This indicates improving operational efficiency and profitability.
• High Return on Invested Capital (ROIC): With an ROIC of 29.1% (excluding cash and goodwill), QGEN generates substantial returns on its investments, a hallmark of a well-managed business.
• Strong Free Cash Flow Conversion: The company’s five-year average profit quality stands at 189.7%, meaning it converts net income into free cash flow at an exceptional rate. This provides financial flexibility for reinvestment, dividends, or debt reduction.
• Manageable Debt Levels: QGEN’s debt-to-free cash flow ratio of 2.77 suggests it could repay its debt in less than three years using current cash flows, reflecting a healthy balance sheet.

Fundamental Analysis Summary

Our fundamental report assigns QGEN a rating of 6 out of 10, highlighting its strengths in profitability and financial health. Key takeaways include:

• Profitability: High operating margins (25.02%) and gross margins (63.82%) place QGEN among the top performers in its industry.
• Valuation: While not cheap, QGEN trades at a discount to industry peers on metrics like P/E and EV/EBITDA.
• Growth Outlook: Analysts expect steady revenue and earnings growth in the coming years, supporting the case for long-term holding.

For investors seeking quality stocks with a mix of growth and financial stability, QGEN presents a compelling case.

Our Caviar Cruise screener lists more quality stocks and is updated regularly.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.